Cogent Biosciences, Inc.
COGT
$34.34
-$0.03-0.09%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 66.60% | 7.38% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 19.36% | 10.28% | |||
| Operating Income | -19.36% | -10.28% | |||
| Income Before Tax | -26.64% | -10.07% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -26.64% | -10.07% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -26.64% | -10.07% | |||
| EBIT | -19.36% | -10.28% | |||
| EBITDA | -19.53% | -10.39% | |||
| EPS Basic | -16.14% | 8.40% | |||
| Normalized Basic EPS | -6.97% | 8.40% | |||
| EPS Diluted | -16.14% | 8.40% | |||
| Normalized Diluted EPS | -6.97% | 8.40% | |||
| Average Basic Shares Outstanding | 9.05% | 20.15% | |||
| Average Diluted Shares Outstanding | 9.05% | 20.15% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||